Literature DB >> 23934363

Therapeutic human cells: manufacture for cell therapy/regenerative medicine.

Christian van den Bos1, Robert Keefe, Carmen Schirmaier, Michael McCaman.   

Abstract

: Human primary cells (e.g. adult stem cells) as well as differentiated cells, including those of the immune system, have been found to be therapeutically useful and free of ethical concerns. Several products have received market authorization and numerous promising clinical trials are underway. We believe that such primary therapeutic cells will dominate the market for cell therapy applications for the foreseeable future. Consequently, production of such cellular products warrants attention and needs to be a fully controlled pharmaceutical process. Thus, where possible, such production should change from manufacture towards a truly scalable industrialized process for both allogeneic and autologous products. Here, we discuss manufacturing aspects of both autogeneic and allogeneic products, review the field, and provide historical context.

Entities:  

Mesh:

Year:  2014        PMID: 23934363     DOI: 10.1007/10_2013_233

Source DB:  PubMed          Journal:  Adv Biochem Eng Biotechnol        ISSN: 0724-6145            Impact factor:   2.635


  5 in total

1.  Applicability of a single-use bioreactor compared to a glass bioreactor for the fermentation of filamentous fungi and evaluation of the reproducibility of growth in pellet form.

Authors:  Winda Soerjawinata; Konstantin Schlegel; Natalie Fuchs; Anja Schüffler; Tanja Schirmeister; Roland Ulber; Percy Kampeis
Journal:  Eng Life Sci       Date:  2021-02-25       Impact factor: 2.678

2.  Theoretical and Practical Issues That Are Relevant When Scaling Up hMSC Microcarrier Production Processes.

Authors:  Valentin Jossen; Cedric Schirmer; Dolman Mostafa Sindi; Regine Eibl; Matthias Kraume; Ralf Pörtner; Dieter Eibl
Journal:  Stem Cells Int       Date:  2016-02-11       Impact factor: 5.443

Review 3.  Manufacturing human mesenchymal stem cells at clinical scale: process and regulatory challenges.

Authors:  Valentin Jossen; Christian van den Bos; Regine Eibl; Dieter Eibl
Journal:  Appl Microbiol Biotechnol       Date:  2018-03-22       Impact factor: 4.813

Review 4.  Mesenchymal Stromal Cells: From Discovery to Manufacturing and Commercialization.

Authors:  Amanda Mizukami; Kamilla Swiech
Journal:  Stem Cells Int       Date:  2018-04-11       Impact factor: 5.443

5.  Pediatric critical care: grand challenges for a glowing future.

Authors:  Kanwaljeet J S Anand
Journal:  Front Pediatr       Date:  2014-04-30       Impact factor: 3.418

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.